Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome
Authors
Keywords
-
Journal
MODERN PATHOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-04-12
DOI
10.1038/s41379-019-0260-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade Prostate Cancer
- (2018) Brandon A. Mahal et al. EUROPEAN UROLOGY
- Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
- (2017) M.J. Duffy et al. EUROPEAN JOURNAL OF CANCER
- Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response
- (2017) Erik Bovinder Ylitalo et al. EUROPEAN UROLOGY
- Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness
- (2017) Sofia Halin Bergström et al. PROSTATE
- Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy
- (2017) Shuang G. Zhao et al. JAMA Oncology
- Aggressive rat prostate tumors reprogram the benign parts of the prostate and regional lymph nodes prior to metastasis
- (2017) Kerstin Strömvall et al. PLoS One
- Molecular Profiles of Prostate Cancer: To Treat or Not to Treat
- (2016) Itay A. Sternberg et al. Annual Review of Medicine
- Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome
- (2016) S. You et al. CANCER RESEARCH
- High Caveolin-1 Expression in Tumor Stroma Is Associated with a Favourable Outcome in Prostate Cancer Patients Managed by Watchful Waiting
- (2016) Peter Hammarsten et al. PLoS One
- Secreted Factors from Colorectal and Prostate Cancer Cells Skew the Immune Response in Opposite Directions
- (2015) Marie Lundholm et al. Scientific Reports
- Adaptive (TINT) Changes in the Tumor Bearing Organ Are Related to Prostate Tumor Size and Aggressiveness
- (2015) Hanibal Hani Adamo et al. PLoS One
- TMPRSS2-ERG Expression Predicts Prostate Cancer Survival and Associates with Stromal Biomarkers
- (2014) Christina Hägglöf et al. PLoS One
- ErbB2 Receptor Immunoreactivity in Prostate Cancer: Relationship to the Androgen Receptor, Disease Severity at Diagnosis and Disease Outcome
- (2014) Peter Hammarsten et al. PLoS One
- Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort
- (2013) G Fisher et al. BRITISH JOURNAL OF CANCER
- The reactive stroma microenvironment and prostate cancer progression
- (2012) David A Barron et al. ENDOCRINE-RELATED CANCER
- Phospho-Akt Immunoreactivity in Prostate Cancer: Relationship to Disease Severity and Outcome, Ki67 and Phosphorylated EGFR Expression
- (2012) Peter Hammarsten et al. PLoS One
- Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance
- (2012) Andreas Josefsson et al. SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY
- The Stroma—A Key Regulator in Prostate Function and Malignancy
- (2012) Christina Hägglöf et al. Cancers
- Prostate Cancer Increases Hyaluronan in Surrounding Nonmalignant Stroma, and This Response Is Associated with Tumor Growth and an Unfavorable Outcome
- (2011) Andreas Josefsson et al. AMERICAN JOURNAL OF PATHOLOGY
- Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice
- (2011) Geert JLH van Leenders et al. MODERN PATHOLOGY
- Mast Cells Are Novel Independent Prognostic Markers in Prostate Cancer and Represent a Target for Therapy
- (2010) Anna Johansson et al. AMERICAN JOURNAL OF PATHOLOGY
- Low Levels of Phosphorylated Epidermal Growth Factor Receptor in Nonmalignant and Malignant Prostate Tissue Predict Favorable Outcome in Prostate Cancer Patients
- (2010) P. Hammarsten et al. CLINICAL CANCER RESEARCH
- Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients
- (2010) S Crnalic et al. ENDOCRINE-RELATED CANCER
- Stromal PDGFRβ Expression in Prostate Tumors and Non-Malignant Prostate Tissue Predicts Prostate Cancer Survival
- (2010) Christina Hägglöf et al. PLoS One
- Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study
- (2009) D M Berney et al. BRITISH JOURNAL OF CANCER
- Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients
- (2009) Pernilla Wikström et al. PROSTATE
- Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer
- (2008) Tobias Zellweger et al. INTERNATIONAL JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started